Pages that link to "Q33777427"
Jump to navigation
Jump to search
The following pages link to An open-label safety study of lapatinib plus trastuzumab plus paclitaxel in first-line HER2-positive metastatic breast cancer. (Q33777427):
Displaying 9 items.
- Taxane acute pain syndrome (TAPS) in patients receiving taxane-based chemotherapy for breast cancer-a systematic review. (Q30251429) (← links)
- Clinicopathological variables predicting HER-2 gene status in immunohistochemistry-equivocal (2 ) invasive breast cancer (Q33995239) (← links)
- Deregulation of the EGFR/PI3K/PTEN/Akt/mTORC1 pathway in breast cancer: possibilities for therapeutic intervention (Q34103963) (← links)
- Skin/nail infections with the addition of pertuzumab to trastuzumab-based chemotherapy. (Q34567451) (← links)
- A Pilot Study of Dose-Dense Paclitaxel With Trastuzumab and Lapatinib for Node-negative HER2-Overexpressed Breast Cancer (Q37143133) (← links)
- SOLTI NeoPARP: a phase II randomized study of two schedules of iniparib plus paclitaxel versus paclitaxel alone as neoadjuvant therapy in patients with triple-negative breast cancer (Q37148642) (← links)
- Efficacy and safety of lapatinib and trastuzumab for HER2-positive breast cancer: a systematic review and meta-analysis of randomised controlled trials (Q37704313) (← links)
- Systemic Therapy for HER2-Positive Central Nervous System Disease: Where We Are and Where Do We Go From Here? (Q38575259) (← links)
- Real-World Data of Triplet Combination of Trastuzumab, Lapatinib, and Chemotherapy in HER2-Positive Metastatic Breast Cancer: A Multicenter Retrospective Study (Q90484041) (← links)